ASX Penny Stocks To Consider In June 2025

The Australian market is facing a cautious start, with ASX 200 futures indicating a slight decline amidst global geopolitical tensions and economic uncertainties. In such times, investors often seek opportunities in lesser-known areas of the market, where penny stocks—despite their somewhat outdated moniker—can still present intriguing possibilities. These stocks, typically representing smaller or newer companies, may offer surprising value when backed by strong financial health.

Top 10 Penny Stocks In Australia

Click here to see the full list of 1,006 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Aussie Broadband (ASX:ABB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Aussie Broadband Limited offers telecommunications and technology services in Australia, with a market capitalization of A$1.17 billion.

Operations: The company's revenue is derived from several segments: Residential (A$628.51 million), Wholesale (A$143.55 million), Business (A$103.00 million), and Enterprise and Government (A$93.51 million).

Market Cap: A$1.17B

Aussie Broadband Limited is actively pursuing growth through mergers and acquisitions, aiming to enhance shareholder value while maintaining financial flexibility. The company has a market capitalization of A$1.17 billion, with revenues from diverse segments including Residential and Wholesale services. Despite having a relatively new management team, Aussie Broadband's earnings have grown by 25% over the past year, outpacing the telecom industry average. However, its net profit margins have slightly declined to 2.5%. The company's debt levels are satisfactory and well-covered by operating cash flow, although insider selling has been significant recently.

• Click here and access our complete financial health analysis report to understand the dynamics of Aussie Broadband.
• Gain insights into Aussie Broadband's future direction by reviewing our growth report.

Dimerix (ASX:DXB)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Dimerix Limited is an Australian biopharmaceutical company focused on developing and commercializing pharmaceutical products for unmet medical needs, with a market cap of A$334.99 million.

Operations: Dimerix generates revenue primarily from its biotechnology segment, which amounts to A$0.74 million.

Market Cap: A$334.99M

Dimerix Limited, an Australian biopharmaceutical company, is pre-revenue with A$0.74 million in earnings from its biotechnology segment and a market cap of A$334.99 million. Despite being debt-free and having sufficient short-term assets to cover liabilities, the company faces challenges due to its unprofitability and increased losses over the past five years. Recent developments include a licensing agreement with Amicus Therapeutics for DMX-200 commercialization in the U.S., alongside positive interim results from Phase 3 trials for FSGS kidney disease treatment. However, Dimerix's share price remains highly volatile amidst these advancements.

• Dive into the specifics of Dimerix here with our thorough balance sheet health report.
• Gain insights into Dimerix's historical outcomes by reviewing our past performance report.

PolyNovo (ASX:PNV)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally with a market cap of A$842.83 million.

Operations: PolyNovo's revenue of A$115.58 million is generated from the development, manufacturing, and commercialization of its NovoSorb technology.

Market Cap: A$842.83M

PolyNovo Limited, with a market cap of A$842.83 million, has shown significant growth in earnings, increasing by 270.2% over the past year and surpassing the industry average. Despite trading at 36.4% below its estimated fair value and having improved profit margins from 1.9% to 5.1%, challenges remain due to negative operating cash flow and a low return on equity of 7.8%. The company's short-term assets exceed both its short-term and long-term liabilities, providing some financial stability despite an inexperienced management team with an average tenure of just 1.4 years.

• Unlock comprehensive insights into our analysis of PolyNovo stock in this financial health report.
• Assess PolyNovo's future earnings estimates with our detailed growth reports.

Taking Advantage

• Gain an insight into the universe of 1,006 ASX Penny Stocks by clicking here.
• Ready For A Different Approach? Rare earth metals are the new gold rush. Find out which 24 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com